BACKGROUND: PD patients often have visual alterations, for example, loss of visual acuity, contrast sensitivity or motion perception, and diminished electroretinogram responses. PD pathology is mainly characterized by the accumulation of pathological α-synuclein deposits in the brain, but little is known about how synucleinopathy affects the retina. OBJECTIVE: To study the correlation between α-synuclein deposits in the retina and brain of autopsied subjects with PD and incidental Lewy body disease. METHODS: We evaluated the presence of phosphorylated α-synuclein in the retina of autopsied subjects with PD (9 subjects), incidental Lewy body disease (4 subjects), and controls (6 subjects) by immunohistochemistry and compared the retinal synucleinopathy with brain disease severity indicators. RESULTS: Whereas controls did not show any phosphorylated α-synuclein immunoreactivity in their retina, all PD subjects and 3 of 4 incidental Lewy body disease subjects had phosphorylated α-synuclein deposits in ganglion cell perikarya, dendrites, and axons, some of them resembling brain Lewy bodies and Lewy neurites. The Lewy-type synucleinopathy density in the retina significantly correlated with Lewy-type synucleinopathy density in the brain, with the Unified Parkinson's disease pathology stage and with the motor UPDRS. CONCLUSION: These data suggest that phosphorylated α-synuclein accumulates in the retina in parallel with that in the brain, including in early stages preceding development of clinical signs of parkinsonism or dementia. Therefore, the retina may provide an in vivo indicator of brain pathology severity, and its detection could help in the diagnosis and monitoring of disease progression.
BACKGROUND:PDpatients often have visual alterations, for example, loss of visual acuity, contrast sensitivity or motion perception, and diminished electroretinogram responses. PD pathology is mainly characterized by the accumulation of pathological α-synuclein deposits in the brain, but little is known about how synucleinopathy affects the retina. OBJECTIVE: To study the correlation between α-synuclein deposits in the retina and brain of autopsied subjects with PD and incidental Lewy body disease. METHODS: We evaluated the presence of phosphorylated α-synuclein in the retina of autopsied subjects with PD (9 subjects), incidental Lewy body disease (4 subjects), and controls (6 subjects) by immunohistochemistry and compared the retinal synucleinopathy with brain diseaseseverity indicators. RESULTS: Whereas controls did not show any phosphorylated α-synuclein immunoreactivity in their retina, all PD subjects and 3 of 4 incidental Lewy body disease subjects had phosphorylated α-synuclein deposits in ganglion cell perikarya, dendrites, and axons, some of them resembling brain Lewy bodies and Lewy neurites. The Lewy-type synucleinopathy density in the retina significantly correlated with Lewy-type synucleinopathy density in the brain, with the Unified Parkinson's disease pathology stage and with the motor UPDRS. CONCLUSION: These data suggest that phosphorylated α-synuclein accumulates in the retina in parallel with that in the brain, including in early stages preceding development of clinical signs of parkinsonism or dementia. Therefore, the retina may provide an in vivo indicator of brain pathology severity, and its detection could help in the diagnosis and monitoring of disease progression.
Authors: Alexa Klettner; Elisabeth Richert; Gregor Kuhlenbäumer; Bernhard Nölle; Kailash P Bhatia; Günter Deuschl; Johann Roider; Susanne A Schneider Journal: Mov Disord Date: 2016-02-16 Impact factor: 10.338
Authors: John M Lee; Pascal Derkinderen; Jeffrey H Kordower; Roy Freeman; David G Munoz; Thomas Kremer; Wagner Zago; Samantha J Hutten; Charles H Adler; Geidy E Serrano; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2017-01-01 Impact factor: 3.685
Authors: Tanya P Lin; Heather Rigby; Jennifer S Adler; Joseph G Hentz; Laura J Balcer; Steven L Galetta; Steve Devick; Richard Cronin; Charles H Adler Journal: J Parkinsons Dis Date: 2015 Impact factor: 5.568
Authors: Douglas G Walker; Lih-Fen Lue; Charles H Adler; Holly A Shill; John N Caviness; Marwan N Sabbagh; Haruhiko Akiyama; Geidy E Serrano; Lucia I Sue; Thomas G Beach Journal: Exp Neurol Date: 2012-11-28 Impact factor: 5.330
Authors: Thomas G Beach; Lucia I Sue; Douglas G Walker; Alex E Roher; LihFen Lue; Linda Vedders; Donald J Connor; Marwan N Sabbagh; Joseph Rogers Journal: Cell Tissue Bank Date: 2008-03-18 Impact factor: 1.522
Authors: Femke Visser; Annemarie M M Vlaar; Carlijn D J M Borm; Valentin Apostolov; Y X Lee; Irene C Notting; Henry C Weinstein; Henk W Berendse Journal: J Neurol Date: 2019-06-18 Impact factor: 4.849
Authors: Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel Journal: Lancet Neurol Date: 2021-08 Impact factor: 44.182